Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Klaudia Urrutia-Pérez
Observed name:
Klaudia Urrutia Pérez
Institution:
Centro de Ingeniería Genética y Biotecnología
Observed institution:
Centro de Ingeniería Genética y Biotecnología
OpenAlex ID:
A5005870040
Safety, Tolerability, and Immunogenicity of a SARS-CoV-2 Recombinant Spike RBD Protein Vaccine: A Randomised, Double-Blind, Placebo-Controlled, Phase 1-2 Clinical Trial (ABDALA Study)
2022
·
Francisco Hernández-Bernal
, Maria C. Ricardo-Cobas
, et al.
·
EClinicalMedicine
·
70
PDF
A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study)
2023
·
Francisco Hernández-Bernal
, Maria C. Ricardo-Cobas
, et al.
·
The Lancet Regional Health - Americas
·
31
Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MEÑIQUE)
2024
·
Francisco Hernández-Bernal
, Joel Quintana-Guerra
, et al.
·
Vaccine
·
3
Safety and pharmacodynamics of intranasal recombinant human interferon alpha-2b as antiviral prophylaxis: A phase I-II clinical trial (OLIVO study)
2025
·
Francisco Hernández-Bernal
, Dania Vázquez-Blomquist
, et al.
·
Next research.
Show more works
View as search
Works count:
5
Citation count:
104
H-index:
3
I10-index:
2
Year
Topic
Type